Breast cancer is according to WHO the second most common cancer in the world. Treatment is usually surgery in combination with chemotherapy and / or radiation and for the majority of patients followed by a 5-year anti-oestrogen therapy to prevent relapse. The project intends to develop a unique p-rod-like implant with the well-known substance (aromatase inhibitors – anti-oestrogen drugs) used to treat and reduce the risk of recurrence of breast cancer. This will be done with the help of unique new pharmaceutical technology, which provides a steady release of the drug for 6-12 months. No such drug is at present available on the market.
Menu